ilf2 antisense oligonucleotide

ILF2 antisense oligonucleotide is a research-stage therapeutic developed by Ionis Pharmaceuticals in collaboration with the MD Anderson Cancer Center. It is designed to target and deplete Interleukin Enhancer Binding Factor 2 (ILF2), a protein that modulates the DNA repair pathway and is overexpressed in approximately 70% of relapsed/refractory multiple myeloma patients, particularly those with 1q21 chromosomal amplification. The oligonucleotide utilizes constrained ethyl (cEt) chemistry to improve RNA affinity, metabolic stability, and tissue half-life. By reducing ILF2 levels, the drug induces DNA damage, inhibits cell proliferation, and enhances the sensitivity of myeloma cells to DNA-damaging agents such as melphalan and bortezomib.

Other names

ILF2-targeting antisense oligonucleotideILF-2-targeting antisense oligonucleotideILF 2-targeting antisense oligonucleotide